Ravulizumab Monitoring Panel, Serum
Use
This test is useful for monitoring the complement blockage by ravulizumab, assessing the response to ravulizumab therapy, the need for dose escalation, potential for dose deescalation or discontinuation of therapy in remission states, and ensuring patients are above a certain ravulizumab concentration for therapy optimization.
Special Instructions
Not provided.
Limitations
The complement blockage assay's performance depends on correct sampling and storage conditions. Degradation by temperature can lead to false results which are hard to differentiate from real complement dysregulation. Ravulizumab concentrations are more reliable as they are not as temperature-sensitive. Testing should be done prior to plasmapheresis or plasma exchange when possible.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
LOINC Codes
- 101923-1 - Ravulizumab pnl SerPl
- 74520-8 - AH50 Act/Nor Ser IA
- 97184-6 - Ravulizumab Ser-mCnc
- 59462-2 - Clinical biochemist review
Result Turnaround Time
3-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL in 2 plastic vials, each vial containing 0.5 mL
Container
Red top (serum gel/SST not acceptable)
Collection Instructions
Draw blood immediately before next scheduled dose. Place tube on wet ice post-collection. Centrifuge at 4°C and aliquot serum into two 5 mL plastic vials. Freeze serum within 30 minutes. Use a room temperature centrifuge if refrigerated one isn't available.
Patient Preparation
Fasting: 8 hours preferred. Discontinue natalizumab 4 weeks prior, if possible.
Storage Instructions
Freeze serum within 30 minutes of centrifugation. Must be placed on dry ice if not frozen immediately.
Causes for Rejection
Gross hemolysis; Gross lipemia
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |